{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:11:19Z","timestamp":1765483879082},"reference-count":23,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ejca.2013.06.017","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T21:46:02Z","timestamp":1376430362000},"page":"3507-3516","source":"Crossref","is-referenced-by-count":21,"title":["A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)"],"prefix":"10.1016","volume":"49","clinical-trial-number":[{"clinical-trial-number":"isrctn93248876","registry":"10.18810\/isrctn"}],"author":[{"given":"Gary","family":"Middleton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Gwyther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Richman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Blake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Napp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Wadsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Maisey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Gollins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun","family":"Myint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Slater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Wagstaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2013.06.017_b0005","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2013.06.017_b0010","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2001.19.18.3801","article-title":"Mortality associated with irinotecan plus bolus fluorouracil\/leucovorin: summary findings of an independent panel","volume":"19","author":"Rothenberg","year":"2001","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2013.06.017_b0015","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jnci\/djm115","article-title":"UGT1A1\u221728 genotype and irinotecan-induced neutropenia: dose matters","volume":"99","author":"Hoskins","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2013.06.017_b0020","first-page":"423","article-title":"Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients","volume":"28","author":"Slatter","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejca.2013.06.017_b0025","first-page":"4725","article-title":"Proficient metabolism of irinotecan by a human intestinal carboxylesterase","volume":"60","author":"Khanna","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2013.06.017_b0030","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1349-7006.1993.tb02031.x","article-title":"Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11","volume":"84","author":"Araki","year":"1993","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.ejca.2013.06.017_b0035","first-page":"3723","article-title":"Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea","volume":"54","author":"Gupta","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2013.06.017_b0040","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0065-2571(94)90023-X","article-title":"ATP-dependent export pumps and their inhibition by cyclosporins","volume":"34","author":"Bohme","year":"1994","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.ejca.2013.06.017_b0045","first-page":"543","article-title":"Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein","volume":"36","author":"Foxwell","year":"1989","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ejca.2013.06.017_b0050","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/00007890-198810000-00008","article-title":"Cholestatic effect of cyclosporine in the rat: an inhibition of bile acid secretion","volume":"46","author":"Le Thai","year":"1988","journal-title":"Transplantation (Baltimore)"},{"key":"10.1016\/j.ejca.2013.06.017_b0055","first-page":"1309","article-title":"Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A","volume":"56","author":"Gupta","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2013.06.017_b0060","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2003.08.049","article-title":"Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer","volume":"21","author":"Chester","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.06.017_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(13)70163-3","article-title":"Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial","author":"Seymour","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.06.017_b0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"JNCI"},{"issue":"31","key":"10.1016\/j.ejca.2013.06.017_b0075","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2013.06.017_b0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1016\/j.ejca.2013.06.017_b0085","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2013.06.017_b0090","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2010.34.5520","article-title":"Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer","volume":"29","author":"Price","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11, Pt. 1","key":"10.1016\/j.ejca.2013.06.017_b0100","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-05-1945","article-title":"ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia","volume":"12","author":"Raaijmakers","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2013.06.017_b0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","volume":"370","author":"Seymour","year":"2007","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ejca.2013.06.017_b0110","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.06.017_b0115","first-page":"219a","article-title":"Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine (CSA)","volume":"16","author":"Fagbemi","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2013.06.017_b0120","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00280-005-1020-5","article-title":"Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer","volume":"56","author":"Desai","year":"2005","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913004929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913004929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T19:04:54Z","timestamp":1563649494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913004929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":23,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0959804913004929"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.06.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}